ArticleACS omega2026
Tumor Lipidomic Changes after Treatment with Polymeric Hydroxychloroquine in a Syngeneic Murine Model of Pancreatic Cancer.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most lethal malignancies, with limited treatment options. Altered lipid metabolism, including dysregulated eicosanoid pathways, plays a role in PDAC progression and therapy resistance. In this study, we investigated the impact of a treatment with polymeric hydroxychloroquine (PCQ), a novel macromolecular derivative of hydroxychloroquine (HCQ), on tumor lipid metabolism in a syngeneic mouse model of PDAC. Using a validated LC-MS/MS method, we quantified 72 eicosanoids in tumors to assess the metabolic changes induced by PCQ and HCQ treatment. Our findings revealed significant PCQ-mediated downregulation of multiple protumorigenic eicosanoids, including PGD2, PGJ2, LTE4, LTB4, and HETEs, and upregulation of antitumor resolvins. This was further confirmed by Partial Least Squares Discriminant Analysis (PLS-DA) and heatmap analysis. The parent compound HCQ showed minimal impact on eicosanoid concentrations in the tumors, with no significant alterations at 24-h and modulation of only six eicosanoids downregulated at 72-h post treatment. Overall, our data highlight a novel role of PCQ in modulating tumor lipid metabolism, suggesting a unique mechanism of action and its potential as an adjuvant agent in the therapy of PDAC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.